Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult
Timothy Wilkin
Timothy Wilkin, Weill Cornell Medical College, New York
A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed multiple regimens. Six month data have now yielded dose and toxicity findings and some preliminary recommendations for therapeutic use.
[audio:https://www.audiomedica.com/podcasting/icaac2005/timothy_wilkin.mp3]